Imeglimin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Imeglimin
Accession Number
DB12509
Type
Small Molecule
Groups
Investigational
Description

Imeglimin has been used in trials studying the treatment of Type 2 Diabetes Mellitus.

Structure
Thumb
Synonyms
Not Available
External IDs
EMD-387008
Categories
Not Available
UNII
UU226QGU97
CAS number
775351-65-0
Weight
Average: 155.205
Monoisotopic: 155.117095439
Chemical Formula
C6H13N5
InChI Key
GFICWFZTBXUVIG-SCSAIBSYSA-N
InChI
InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
IUPAC Name
(6R)-N4,N4,6-trimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
SMILES
C[C@@H]1NC(N)=NC(=N1)N(C)C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
24812808
PubChem Substance
347828740
ChemSpider
26232690
Wikipedia
Imeglimin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedOtherDrug Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics1
1CompletedTreatmentBioequivalence1
1CompletedTreatmentQt Interval, Variation in1
1CompletedTreatmentType 2 Diabetes Mellitus1
1RecruitingTreatmentHepatic Impairment1
2CompletedTreatmentType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.63 mg/mLALOGPS
logP-0.92ALOGPS
logP-0.69ChemAxon
logS-1.5ALOGPS
pKa (Strongest Acidic)19.01ChemAxon
pKa (Strongest Basic)10.22ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area66.01 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity43.29 m3·mol-1ChemAxon
Polarizability16.61 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminotriazines. These are organic compounds containing an amino group attached to a triazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Triazines
Sub Class
Aminotriazines
Direct Parent
Aminotriazines
Alternative Parents
1,3,5-triazines / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Hydrocarbon derivatives / Amines
Substituents
Aminotriazine / 1,3,5-triazine / Guanidine / Azacycle / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidamide / Organic nitrogen compound / Hydrocarbon derivative / Organonitrogen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 16:40 / Updated on June 04, 2019 07:39